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Abstract
Background: Aromatase, the key enzyme in estrogen biosynthesis, is encoded by the Cyp19a1
gene. Thus far, 3 unique untranslated first exons associated with distinct promoters in the mouse
Cyp19a1 gene have been described (brain, ovary, and testis-specific). It remains unknown whether
aromatase is expressed in other mouse tissues via novel and tissue-specific promoters.
Methods: Real-time PCR was used to examine the aromatase expression levels in various C57BL/
6 mouse tissues. 5'-rapid amplification of cDNA ends (5'-RACE) was used to determine the
transcriptional start sites of Cyp19a1 transcripts. Promoter activity was measured using serial
deletion mutants of DNA fused to the luciferase reporter gene. Primary mouse adipose fibroblasts
were isolated and cultured from 16-week-old mouse gonadal fat pads.
Results: We systematically analyzed Cyp19a1 expression in a large number of mouse tissues, and
demonstrated for the first time that aromatase was expressed in the male but not female gonadal
fat pad. Subcutaneous and brown adipose tissue did not contain detectable Cyp19a1 mRNA. We
used 5'-RACE to clone a novel gonadal fat-specific untranslated first exon, which is spliced onto a
common junction 15 bp upstream of the translation start site. This adipose-specific first exon was
mapped to approximately 75 kb upstream of the translation start site. Transfection of luciferase
reporter gene plasmids containing the promoter region upstream of the adipose-specific first exon
into murine 3T3-L1 adipose fibroblasts demonstrated significant basal promoter activity conferred
primarily by the sequence located at -343/-1 bp. Dexamethasone significantly induced activity of this
adipose-specific promoter region. Adipose-specific Cyp19a1 mRNA was expressed in primary
mouse adipose fibroblasts and significantly induced by dexamethasone alone or serum plus
dexamethasone.
Conclusion:  Taken together, this research identified a novel, adipose-specific first exon of
Cyp19a1 and its hormonally regulated promoter region in male murine gonadal fat. These results
expand the known 5'-regulatory region of the murine Cyp19a1 gene to 75 kb upstream of the
translation start site. Cyp19a1 expression in mouse adipose tissue may play an important role in
reproductive biology and lipid metabolism.
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Background
Aromatase cytochrome P450 is the key enzyme for estro-
gen biosynthesis that converts androstenedione and testo-
sterone to estrone and 17β-estradiol, respectively [1]. The
biologically active estrogen, 17β-estradiol, functions pri-
marily via binding to its receptors, estrogen receptor-α [2-
4] and estrogen receptor-β [5]. Beyond its essential role in
reproductive function [6], estrogen is also involved in vas-
cular biology [7,8], lipid and carbohydrate metabolism
[9,10], bone mineralization [11], and cognitive and other
brain-related functions [1,12]. Estrogen is also essential
for the initial development and further growth of a
number of benign and malignant hormone-dependent
disorders [6].
Aromatase is encoded by the CYP19A1 gene in humans,
which spans approximately 123 kb on chromosome
15q21.2. The ATG translational start site is located in cod-
ing exon II, and the coding region of aromatase protein is
found within 30 kb of the 3'-end and contains nine exons
(II-X) [6]. The 93-kb 5'-flanking region upstream of the
coding region contains a number of alternative untrans-
lated first exons, the expression of which is driven by mul-
tiple tissue-specific promoters [13]. These promoters
differentially regulate expression of aromatase in gonads,
adipose tissue, bone, brain, skin, fetal liver, and placenta
[14]. Thus far, 10 alternative tissue-specific first exons
have been found in the human, including exon I.1, I.2
and I.2a in placenta, I.4 in adipose tissue and skin, I.5 in
fetal tissues, I.f in brain, I.7 in endothelial cells, I.6 in
bone, I.3 in adipose tissue, and PII in gonads. The most
proximal promoter, PII, and 2 other proximal promoters,
I.3 and I.6, are within the 1-kb region upstream of the
ATG translational start site, whereas promoter I.4 is
located 73 kb upstream of exon II. The most distally
located promoter, I.1, is found approximately 93 kb
upstream of the coding region. All of these 5'-untranslated
first exons are spliced onto a common junction located 38
bp upstream of the ATG translational start site. Conse-
quently, the aromatase protein is the same regardless of
the splicing pattern [15].
In mice, aromatase is encoded by a single gene, Cyp19a1,
located on chromosome 9. Similar to humans, the ATG
translation start site lies in coding exon II and the coding
region of aromatase protein is found in the downstream
29-kb portion of the gene and contains 9 exons (II-X)
[16]. In contrast to the human gene, only 3 tissue-specific
untranslated first exons of the mouse Cyp19a1 gene have
been reported, including an ovary-specific first exon
(Eov), a testis-specific first exon (Etes), and a brain-spe-
cific first exon (Ebr). To generate mouse tissue-specific
aromatase transcripts, a tissue-specific first exon is spliced
onto a common coding region as a result of the activation
of its upstream promoters, which regulate aromatase
expression in the ovary, testis, or brain. The mouse ovary-
and brain-specific first exons share 100% and 93%
homology with the human exons PII and I.f, whereas the
recently discovered testis-specific first exon is unique to
the mouse. According to a previous study, the entire
mouse  Cyp19a1  locus is approximately 60 kb. The 3
untranslated first exons and their flanking promoter
regions span more than 30 kb, whereas the 9 coding exons
are restricted to about 29 kb. Promoters for Ebr and Etes
are located about 31 kb and 10 kb upstream of the trans-
lation start site. As in other species, the promoter for Eov
is the most proximal promoter, located 121 bp upstream
of the translation start site [17,18].
In the human, extragonadal aromatase expression plays a
key role in estrogen production, especially in men and in
postmenopausal women, in whom ovarian aromatase
expression ceases after menopause [6,19,20]. In particu-
lar, skin and adipose fibroblasts express physiologically
significant levels of aromatase to produce sufficient quan-
tities of estrogen, which may prevent bone loss in both
sexes or contribute to endometrial hyperplasia or cancer
in women [21,22]. Promoter I.4 is primarily responsible
for regulating aromatase expression in adipose tissue and
skin in humans [23]. Aromatase expression, however, has
not been reported in mouse adipose or skin tissue. Thus,
we were particularly interested in determining whether
aromatase is expressed in mouse extragonadal tissues,
including fat or skin, and whether a novel promoter com-
parable to the human promoter I.4 regulates peripheral
aromatase expression in mice.
Methods
Animals
Animals were housed according to the National Institutes
of Health Guide for the Care and Use of Laboratory Ani-
mals. All procedures were approved by the Northwestern
University Animal Care and Use Committee. All tissues
were harvested from mice with a C57BL/6J background.
Mice were maintained on a 14-hour light:10-hour dark
cycle with standard chow (7912; Harlan Teklad, Madison,
WI) and water ad libitum.
Quantitative real-time RT-PCR
Total RNA from various mouse tissues was extracted at 10
and 16 weeks of age using TRIzol reagent according to the
manufacturer's instructions (Sigma, St. Louis, Missouri,
USA). cDNA was synthesized using oligo (dT) primers
with superscript™ III first-strand kit as recommended by
the supplier (Invitrogen, Carlsbad, California, USA). Real-
time PCR was performed with the Power SYBR® green PCR
kit according to the manufacturer's instructions (Applied
Biosystems, Foster City, California, USA) in an ABI 7900
HT fast real-time PCR system (Applied Biosystems). The
primers used were as follows:Reproductive Biology and Endocrinology 2009, 7:37 http://www.rbej.com/content/7/1/37
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Cyp19a1 forward: 5'-CTG CAG ACA CTA CTA CTA CA-3'
Cyp19a1 reverse: 5'-ATC CGA GTC ACT GCT CTC AG-3'
GAPDH forward: 5'-TGT TAC CAA CTG GGA CGA CA-3'
GAPDH reverse: 5'-GGG GTG TTG AAG GTC TCA AA-3'
To generate external standard curves for each run, mouse
aromatase and GAPDH cDNAs were amplified from ovar-
ian tissue and cloned into the pCR®II-TOPO plasmid (Inv-
itrogen). The following standard primers were used:
standard Cyp19a1 forward: 5'-GCT GAA CCC CAT GCA
GTA TAA-3'
standard Cyp19a1 reverse: 5'-AGC CAA AAG GCT GAA
AGT ACC-3'
standard GAPDH forward: 5'-CCG CAT CTT CTT GTG
CAG T-3'
standard GAPDH reverse: 5'-TCC ACC ACC CTG TTG
CTG TA-3'
Different concentrations (10-1 to 10-12 μg DNA/μl) of plas-
mid DNA were amplified with the real-time PCR primers
using the Power SYBR® green PCR kit as standard curves.
Copy numbers in various tissues were calculated relative
to the amount of total RNA used. The ratio of copy num-
bers of Cyp19a1 (× 107) to copy numbers of GAPDH was
calculated as Cyp19a1 mRNA levels. Pituitary RNA was
analyzed from pools of 5 animals. Each pool was meas-
ured in at least 3 independent reverse transcription (RT)
reactions, and the mean and SEM were calculated. Other
tissues were measured as individual samples. Real-time
PCR cycler conditions were 50°C for 2 minutes; 95°C for
10 minutes; and 40 cycles of 95°C for 15 seconds and
60°C for 1 minute.
5'-rapid amplification of cDNA ends (5'-RACE)
To determine the transcriptional start sites of Cyp19a1
transcripts from various tissues, 5'-RACE was performed
using the SMART™ RACE cDNA amplification kit (Clon-
tech, Mountain, California, USA). One microgram of total
RNA from each tissue (ovary, testis, hypothalamus, or
male gonadal fat) underwent RT with a modified oligo
(dT) primer. After PowerScript RT reached the end of the
mRNA template, it added several dC residues. The SMART
II™ A oligonucleotide annealed to the tail of the cDNA
and served as an extended template for PowerScript RT.
The primary touchdown PCR reverse primer (5'-GAC TCT
CAT GAA TTC TCC ATA CAT CT-3', Figure 3A), binding to
exon 3 and 4 coding sequence, was combined with the
universal primer A mix provided with the kit. If the pri-
mary PCR reaction failed to give the distinct bands of
interest, a secondary, or "nested" PCR reaction was per-
formed with the reverse nested primer (5'-AAT GAG GGG
CCC AAT TCC CAG A-3', Figure 3A), binding to exon 2
coding region, combined with the nested universal primer
A. RACE products were cloned into the pCR®-TOPO TA
cloning vector and subsequently sequenced.
Exon-specific RT-PCR and real-time RT-PCR 
amplification
Total RNA was extracted from various mouse tissues and
treated with the TURBO DNase following the standard
protocol (Applied Biosystems). The treated RNA was then
reverse transcribed using oligo (dT) primers with super-
script™ III first-strand RT kit according to the instructions
of the manufacturer (Invitrogen Corp.). To amplify the
transcript variants in male gonadal adipose tissue, ovary,
testis, and brain (Tad, Tov, Ttes, and Tbr), the sequence
information of RACE products was used to design forward
primers that bound the 5' untranslated regions (5' UTR)
of these transcripts. The reverse primers were located in
coding exon II. The following primer pairs were used:
Tad forward: 5'-GTT CTG GTC AGC ACA CCA ACT-3'
Tad reverse: 5'-AGA CGA GCT CTC ACA ATT CCA-3'
Tov forward: 5'-CAC CAC TGC TTT CTT CCC ATA-3'
Tov reverse: 5'-AGA CGA GCT CTC ACA ATT CCA-3'
Ttes forward: 5'-GGT TAC CAT GGG GAA CGA A-3'
Ttes reverse: 5'-ATT CCC AGA CAG TAG CCA GGA-3'
Tbr forward: 5'-CTG CGC ATC ATT AGC AAA ACT-3'
Tbr reverse: 5'-AGA CGA GCT CTC ACA ATT CCA-3'
The PCR cycler conditions were 95°C for 4 minutes; 35
cycles of 94°C for 30 seconds, 60°C for 30 seconds, and
72°C for 1 minute; and a final extension of 72°C for 9
minutes.
Real-time PCR cycler conditions were 50°C for 2 minutes;
95°C for 10 minutes; and 40 cycles of 95°C for 15 sec-
onds and 60°C for 1 minute.
Plasmids, transfections, and luciferase assays
The potential promoter regions of an adipose-specific
transcript (343 bp and 1637 bp upstream of transcrip-
tional start site) were amplified by PCR. The primers were
introduced at the restriction enzyme KpnI and BglII sites.Reproductive Biology and Endocrinology 2009, 7:37 http://www.rbej.com/content/7/1/37
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The PCR fragments were then digested and subcloned into
a pGL4.10 [luc2] luciferase vector. Briefly, the promoter
region was cloned into the location between a synthetic
poly (A) signal/transcriptional pause site and the luc2
gene of the pGL4.10 [luc2] vector (Promega, Madison,
Wisconsin, USA). All constructs were reconfirmed by
sequencing. The primers amplifying the promoter region
were:
-343 forward: 5'-ATA GGT ACC CCA CGA TAA GGG ACT
TGA TGA-3'
-1637 forward: 5'-ATA GGT ACC TCT CAT CGT CTG ATG
TTC TGG-3'
-343 and -1637 reverse: 5'-ATT AGA TCT ACG GAA TCC
CCA CCC TGC CTC A-3'
Mouse 3T3 L1 cells were transfected with each of the pro-
moter constructs using Lipofectamine™ 2000 transfection
reagent (Invitrogen) according to the manufacturer's pro-
tocol. Reporter plasmid (4 μg) and a pGL4.74 [hRluc]
internal control (0.4 μg) were transfected per well of 6-
well plate for 24 hours. Following serum starvation, cells
were maintained in DMEM supplemented with 10% fetal
bovine serum (FBS) in the absence or presence of 250 nM
dexamethasone for 24 hours, and total protein lysate was
collected and assayed for luciferase activity.
Primary mouse adipose fibroblast (MAF) culture and 
hormone treatment
Mouse gonadal fat pads were harvested from 16-week-old
mice. Isolation and culture of primary MAFs were per-
formed according to the modified previous protocol for
culturing human breast adipose fibroblasts [24]. In brief,
adipose tissues were minced and digested with colla-
genase B (1 mg/ml) at 37°C for 30 minutes. Single-cell
suspensions were prepared by filtration through a 75-μm
sieve. Fresh cells were suspended in DMEM/F-12 contain-
ing 10% FBS. Twelve to 24 hours after fibroblast attach-
ment, culture medium was changed at 48-hour intervals.
Cells were grown to confluence and placed in serum-free
medium for 16 hours. MAFs were incubated in serum-free
DMEM/F-12 medium or DMEM/F-12 supplemented with
10% FBS in the absence or presence of 250 nM dexameth-
asone or 500 nM Dibutyryl cAMP (Bt2cAMP) plus 100
μM phorbol diacetate (PDA) for 24 hours. Cell extracts
were prepared as previously described for real-time RT-
PCR [25].
Statistical analysis
Results are expressed as mean ± SEM. Statistically signifi-
cant differences at p < 0.05 were determined by 1-way
ANOVA followed by t-test.
Results
Expression of the Cyp19a1 gene in male mouse gonadal 
fat
To determine Cyp19a1 mRNA expression in mouse tis-
sues, 10-week-old mice were euthanized and multiple tis-
sues were collected and analyzed by quantitative real-time
RT-PCR. After 40 cycles of PCR, if the Ct value is underde-
termined, we considered Cyp19a1 mRNA below the level
of detection. As expected, aromatase mRNA was detected
in the testis and epididymis in males, the ovary in females,
and the hypothalamus and pituitary in both sexes (Figure
1). Neither male nor female mice had detectable Cyp19a1
mRNA in lung, liver, kidney, spleen, bone, stomach, intes-
tine, heart, aorta, muscle, or skin. Cyp19a1 mRNA was
also below the level of detection from the uterus, mam-
mary gland, and vas deferens (data not shown). A system-
atic analysis of adipose tissues from various body sites was
also performed. We demonstrated for the first time that
aromatase was expressed in the male but not female
gonadal fat pad. Subcutaneous and brown adipose tissue
did not contain detectable Cyp19a1 mRNA.
Cyp19a1 mRNA levels in various male and female mouse
tissues are illustrated in Figure 1. The highest levels of
Cyp19a1 mRNA were found in the ovary and testis, fol-
lowed by the hypothalamus and epididymis, whereas the
lowest levels were detected in the male gonadal fat and
pituitary.
We next determined whether Cyp19a1 expression in male
gonadal fat varied with age or amount of tissue. While
gonadal fat pad weight increased by 43% in 16-week-old
mice compared with 10-week-old mice (Figure 2A),
Cyp19a1 mRNA levels were not significantly different
(Figure 2B).
Isolation of a novel untranslated gonadal adipose tissue-
specific first exon of the Cyp19a1 gene
To determine whether the transcription initiation site and
the untranslated first exon of Cyp19a1  transcripts in
gonadal fat were different than those of previously pub-
lished sequences, we performed 5'-RACE (Figure 3A).
Nine 5'-RACE clones from male gonadal fat (n = 3) were
isolated and identified as Cyp19a1 transcripts (Ensembl
Transcript ID: ENSMUST00000034811). The nucleotide
sequence of the 5' region of aromatase adipose-specific
transcript (Tad) is shown in Figure 3B (GenBank acces-
sion number: EU252014, date of accession: Nov. 1,
2009). The untranslated first exon in gonadal fat was 93
bp and was located 74763 bp upstream of the transla-
tional start site. The 5' UTRs of the 9 isolated clones were
identical and were not similar to any previously known
Cyp19a1 transcript sequence.Reproductive Biology and Endocrinology 2009, 7:37 http://www.rbej.com/content/7/1/37
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5'-RACE clones from 3 other tissues (ovary, testis, and
brain) were analyzed as controls. Five clones from the
ovary had identical transcriptional start sites (position
221 of EMBL/GenBank accession number D67046), and
the sequences of the 5' UTRs of the ovarian transcripts
(Tov) were identical to ovarian Cyp19a1 cDNA described
previously [18]. Cyp19a1  transcripts from 8 5'-RACE
clones were identified as brain aromatase cDNA (Tbr)
[17]. The transcription start site in male mice was at posi-
tion 382 of EMBL/GenBank accession number D67045,
which was 47 nucleotides upstream from that described
previously [17]. The transcription start site in female mice
was at position 444 of EMBL/GenBank accession number
D67045, 15 nucleotides downstream from that described
previously (17). The transcription start site of the testis-
specific transcript (Ttes) was located at position 1589 of
EMBL accession number AJ437576, which was 18 nucle-
otides downstream from that described by Vanselow et al.
[16]. The small discrepancy between our results and pre-
vious published data with respect to the presumed tran-
scription start sites of brain- and testis-specific Cyp19a1
mRNAs may be due to a range of possible initiation sites
within a confined region or slightly different techniques
used in various laboratories.
Expression of mouse Cyp19a1 adipose-specific transcript 
in various tissues
To determine the distribution of Tad, Tov, Ttes, and Tbr in
male gonadal fat, ovary, testes, and hypothalamus, exon-
specific RT-PCR analysis of RNAs was performed using 5'-
UTR-specific forward primers and reverse primers located
in coding exon II. Tad and Tov were expressed in male
gonadal fat (Figure 4A). Those results were confirmed by
real-time RT-PCR in 10-week-old and 16-week-old mouse
gonadal fat (Figure 4B). Tbr and Tov were found in the
hypothalamus. Tov was the only Cyp19a1  transcript
expressed in the ovary. All 4 transcripts were found in the
testis, though Tov was the major transcript. Thus, we sug-
gested renaming the previously described Tov as gonadal-
specific transcript (Tgon).
Male gonadal adipose-specific promoter activity
In order to characterize promoter activity of the newly
identified male gonadal fat-specific transcript, we gener-
ated 2 luciferase reporter constructs containing -343/-1
and -1637/-1 bp of the 5' sequence and assessed their
activity in luciferase reporter assays. As compared with the
empty control vector, luciferase activity was increased by
1.7 fold in cells transfected with the -343/-1 construct, and
decreased by 3.7 fold in cells transfected with the -1637/-
1 construct (Figure 5A). This result indicated that basal
promoter activity is conferred by a sequence located
within -343/-1 bp and there may be a negative regulatory
sequence within the -1637/-343 bp region of the pro-
moter. Luciferase activity of the empty vector was not
altered following dexamethasone treatment, whereas
activity of the -343/-1 promoter increased by 1.6 fold after
treatment with dexamethasone compared with vehicle. In
the presence of dexamethasone, luciferase activity of -
1637/-1 increased by 3.4 fold as compared with vehicle
treatment. Both basal and dexamethasone-stimulated
promoter activity levels were significantly diminished in -
1637/-1 compared with the -343/-1 sequence. Although
dexamethasone response was preserved in both, this is
suggestive of a general silencer-type element in the -1637/
-343 region, which does not eliminate glucocorticoid
action. Bt2cAMP plus PDA did not induce activity of the
gonadal adipose-specific Cyp19a1 promoter (Figure 5B).
Cyp19a1 gene expression in 10- and 16-week-old male  mouse gonadal fat Figure 2
Cyp19a1 gene expression in 10- and 16-week-old 
male mouse gonadal fat. (A) Gonadal fat pad weight as 
percentage of body weight. (B) Cyp19a1 mRNA levels in male 
mouse gonadal fat were measured by real-time RT-PCR. 
Data are expressed as mean ± SE with n = 5–8 mice in each 
group. *p < 0.05 for 16-week-old mice vs. 10-week-old mice.
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The level of Cyp19a1 mRNA in 10-week-old mouse tissues  measured by real-time RT-PCR Figure 1
The level of Cyp19a1 mRNA in 10-week-old mouse 
tissues measured by real-time RT-PCR. Cyp19a1 and 
GAPDH cDNAs from mouse ovary were cloned into 
pCR®II-TOPO plasmid vector. Different concentrations (10-1 
to 10-12 μg DNA/μl) of plasmid DNAs containing Cyp19a1 or 
GAPDH sequence were amplified with primers for Cyp19a1 
or GAPDH as the external standard curves. The ratio of 
copy numbers of Cyp19a1 (× 107) to copy numbers of 
GAPDH was calculated as Cyp19a1 mRNA levels. Pituitary 
was analyzed from pools of 5 animals. Data are expressed as 
mean ± SE with n = 5 mice in each group.
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Dexamethasone plus fetal bovine serum stimulated 
Cyp19a1 mRNA expression in primary MAFs
The literature indicates that hormonal treatments with
broad actions such as PKA stimulators (cAMP analogs),
PKC stimulators (phorbol esters), glucocorticoids and
serum, alone and in combination, regulated aromatase
expression in human adipose fibroblasts via different pro-
moters[26,27]. To determine aromatase expression and
regulation in MAFs, mouse gonadal fat pads were har-
vested and primary MAFs were cultured. Based on our
results regarding the activity of the adipose tissue pro-
moter (Figure 5), we treated these cells with vehicle, dex-
amethasone, FBS, or dexamethasone plus FBS. We
quantitated the levels of various promoter-specific
Cyp19a1  mRNA expressed using exon-specific real-time
RT-PCR. Adipose-specific Cyp19a1 mRNA levels were sig-
nificantly increased by 2.5 fold upon dexamethasone
treatment and further significantly increased to 7.8 fold
following dexamethasone plus FBS treatment. Dexameth-
asone, FBS, or dexamethasone plus FBS treatment did not
significantly alter ovarian-specific Cyp19a1 mRNA levels.
Although total Cyp19a1 mRNA levels were increased by
4.5 fold following dexamethasone treatment as compared
to vehicle treatment, statistically this result did not rise
above the level of significance. FBS alone had no effect on
Cyp19a1  expression, but significantly augmented the
effect of dexamethasone to cause a 15-fold increase in
Cyp19a1 expression (Figure 6).
Discussion
In humans and mice, Cyp19a1 gene expression is control-
led by various tissue-specific promoters that drive the
transcription of untranslated tissue-specific first exons
together with the common coding exons II-X to generate
aromatase [6,13]. Thus far, 2 adipose tissue-specific first
exons in humans have been identified, exons I.4 and I.3,
located 73 kb and within 1 kb upstream of the transla-
tional start site, respectively. Here, we demonstrated for
the first time the presence of an adipose tissue-specific
untranslated Cyp19a1 first exon in male, but not female,
mouse gonadal fat.
The mouse Cyp19a1 gene, including 3 unique untrans-
lated first exons, is expressed in ovary, testis, and brain
[16]. A previous study showed that the brain-specific first
exon is the most distally located first exon in mice, 31 kb
upstream of the translational start site [17]. Here, we
found that the gonadal-fat specific first exon is located 75
kb upstream of the translational start site (Figure 7). We
assumed some similarities between human exon I.4 and
the mouse adipose-specific first exon (Ead). However,
analysis of the sequence of exon I.4 and Ead showed no
significant similarity, nor did the Ead sequence show sim-
ilarities to any other previously reported exons in humans
or mice using the BLAST (Basic Local Alignment Search
Tool). Thus, our results extended the Cyp19a1  5' UTR
from 31 kb up to 75 kb upstream of the first coding exon.
Based on our data, the mouse Cyp19a1 gene now includes
at least 104 kb of genomic sequence on chromosome 9.
This newly identified Tad was expressed in male gonadal
fat and testis, and was not found in ovary or brain. It has
been shown that Tgon is the principle transcript variant in
the mature ovary [18]. A previous study also showed that
Tgon is expressed in the testis and brain [16], and we
found that Tgon was also expressed in adipose tissue. Tbr
was only expressed in brain and testis, which was not con-
sistent with a previous study which also described ovarian
Isolation of a Cyp19a1 transcript with an untranslated adipose-specific first exon in male mouse gonadal fat Figure 3
Isolation of a Cyp19a1 transcript with an untranslated adipose-specific first exon in male mouse gonadal fat. (A) 
Schematic representation of relationship of gene-specific primers to Cyp19a1 cDNA template for 5'-RACE. (B) Nucleotide 
sequence of the 5' region of Cyp19a1 cDNA isolated from male mouse gonadal fat. Arrows indicate the 5'-boundary of region 
encoded by exon II of the Cyp19a1 gene. The lower case letters show the unique DNA sequence of the adipose-specific first 
exon. ATG indicates the translational start site.
Untranslated Exon I Exon II Exon III Exon IV
Touchdown primer Nested primer
AUG
CCC 5’ 3’
Universal primer A or 
Nested universal primer A 
A
aattccaggatgggatgctggccttggctgtagggggcatacacatctggagcctggccggaggtctttgttctggtcagcacaccaactcagGCCAAATAGCGCAAGATG
B
common splice siteReproductive Biology and Endocrinology 2009, 7:37 http://www.rbej.com/content/7/1/37
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expression of Tbr. As shown in the previous study [16],
Ttes was uniquely expressed in testis, but we also found
that Tgon was the major Cyp19a1 transcript in testis.
CYP19A1 expression in premenopausal women is mainly
found in ovarian follicles, and estrogen functions as a cir-
culating hormone on distal target tissues. Conversely,
local estrogen synthesis in extragonadal tissues, such as
adipose tissue, plays a more predominant role in men and
postmenopausal women [28,29]. Regional variations in
CYP19A1 expression in subcutaneous adipose tissue have
been observed in humans, and its expression in buttocks
and thighs is 2- to 3-fold greater than that in subcutaneous
abdominal tissue and breast tissue [30]. In the present
study, we showed regional variations of Cyp19a1 expres-
sion in mice. Cyp19a1  was expressed in male, but not
female, mouse gonadal fat, and there was no Cyp19a1
expression in subcutaneous fat or brown adipose tissue in
either sex.
The CYP19A1 transcripts in human breast adipose tissue
contain exon I.4 followed by exon 1.3 and II. In adipose
stromal cells, the transcription of I.3 and II is stimulated
by cAMP or prostaglandin E2. Promoter I.4 contains the
interferon γ activation element followed by a glucocorti-
coid response element that is a SP1-binding site, and I.4
expression is stimulated by class I cytokines and TNFα
through the JAK1/STAT3 pathway [1]. We found that
Cyp19a1 promoter activity in male mouse gonadal fat was
induced by dexamethasone, and did not change after
Bt2cAMP plus PDA treatment. Adipose-specific Cyp19a1
mRNA expression in primary MAF was increased by dex-
amethasone and augmented by FBS. This response is sim-
ilar to that seen in human promoter I.4 activation, which
is enhanced by binding of glucocorticoid receptors to glu-
cocorticoid response elements. We also performed a TF
search for cis-regulating elements in the new adipose pro-
moter and found three half glucocorticoid response ele-
ments(GREs) located at -139/-134, -163/-159,-316/-
311bp. Thus, it is likely that this new mouse adipose-spe-
cific aromatase promoter has a similar regulatory profile
to the human adipose/skin promoter I.4, which has bind-
ing sites for glucocorticiod receptor. Our results from both
Ead luciferase reporter assay and primary cultured mouse
adipose fibroblasts support this notion. The promoter
activity of the Cyp19a1 transcript in male mouse gonadal
fat may also be induced through JAK1/STAT3 pathway.
Thus, cytokines in serum may function synergistically
with glucocorticoid to activate this promoter [31].
Regulation of the adipose-specific promoter of the Cyp19a1  gene by dexamethasone (A) and Bt2cAMP plus PDA (B) Figure 5
Regulation of the adipose-specific promoter of the 
Cyp19a1 gene by dexamethasone (A) and Bt2cAMP 
plus PDA (B). Luciferase plasmids containing the 5'-flanking 
promoter region of the mouse Cyp19a1 gene in gonadal fat (-
343/-1 bp and -1637/-1 bp) were transfected into murine 3T3 
L1 cells for 24 hours. pGL4.74 [hRluc] Renilla was used as an 
internal control for transfection efficiency. Promoter activity 
was normalized to pGL4.74 [hRluc] Renilla and was repre-
sented as the average of data from triplicate replicates; the 
empty luciferase vector PGL4.10 [luc2] without treatment 
was arbitrarily assigned a unit of 1, and results are expressed 
as multiples of the PGL4.10 [luc2] vector. All results are 
given as mean ± SE from at least 3 independent experiments 
performed in triplicate. *p < 0.05 for vs. the empty luciferase 
vector PGL4.10 [luc2] without treatment. †p < 0.05 for vs. 
vehicle treatment.
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Expression of adipose-specific transcripts of the Cyp19a1  gene in different mouse tissues using RT-PCR (A) and in  gonadal fat using real-time RT-PCR(B) Figure 4
Expression of adipose-specific transcripts of the 
Cyp19a1 gene in different mouse tissues using RT-
PCR (A) and in gonadal fat using real-time RT-
PCR(B). Tissue-specific primer pairs were used. Each for-
ward primer was located in the tissue-specific first exon. 
Reverse primers were located in coding exon II. Tad: tran-
script in adipose tissue, Tgon: transcript in gonad, Ttes: tran-
script in testis, Tbr: transcript in brain, M: DNA ladder.
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Estrogens play an important role in the maintenance of
lipid homeostasis [32]. The aromatase knockout (ArKO)
mouse cannot synthesize endogenous estrogens, and cir-
culating estradiol levels are at the limit of detection. ArKO
mice develop an age-dependent increase in intra-abdomi-
nal adiposity. The increase in adipose tissue is associated
with hyperplasia and hypertrophy of the adipocytes with
a simultaneous decrease in lean mass and development of
hypercholesterolemia, hyperleptinemia, and insulin
resistance [9,33]. Total body fat is also increased in 16-
week-old mice in estrogen receptor α and/or β knockout
mice [34-36]. Aromatase-deficient patients show a similar
phenotype characterized by impaired lipid and insulin
metabolism [14]. In our study, we found that Cyp19a1
was expressed in male mouse adipose tissue. In addition
to circulating estradiol, locally produced estradiol in male
mouse gonadal fat may play an important physiologic
role in regulating lipid metabolism. Moreover, estrogen
produced in gonadal fat may exert local physiologic
effects on testicular maturation.
In summary, we have shown Cyp19a1 expression in male
mouse gonadal fat, isolated an adipose-specific untrans-
lated first exon, and demonstrated dexamethasone-regu-
lated promoter activity of the adipose-specific Cyp19a1
transcript. Together with other studies [16-18], these
results suggest that in mice, at least 4 different promoters
actively regulate Cyp19a1  expression in adipose tissue,
gonads, and brain. These results expanded the 5'-regula-
tory region of the murine Cyp19a1 gene to 75 kb upstream
of the translation start site (Figure 7). Further studies are
necessary to identify the cis-regulatory elements and tran-
scriptional factors that regulate the novel gonadal fat-spe-
cific Cyp19a1 promoter.
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